About xenetic biosciences inc - XBIO
Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.
XBIO At a Glance
Xenetic Biosciences, Inc.
945 Concord Street
Framingham, Massachusetts 01701
| Phone | 1-781-778-7720 | Revenue | 2.98M | |
| Industry | Pharmaceuticals: Major | Net Income | -2,680,860.00 | |
| Sector | Health Technology | 2025 Sales Growth | 19.043% | |
| Fiscal Year-end | 12 / 2026 | Employees | 2 | |
| View SEC Filings |
XBIO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.241 |
| Price to Book Ratio | 0.672 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 1.478 |
| Enterprise Value to Sales | -1.408 |
| Total Debt to Enterprise Value | N/A |
XBIO Efficiency
| Revenue/Employee | 1,488,205.50 |
| Income Per Employee | -1,340,430.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.39 |
XBIO Liquidity
| Current Ratio | 8.316 |
| Quick Ratio | 8.316 |
| Cash Ratio | 8.144 |
XBIO Profitability
| Gross Margin | N/A |
| Operating Margin | -95.235 |
| Pretax Margin | -90.07 |
| Net Margin | -90.07 |
| Return on Assets | -35.124 |
| Return on Equity | -40.004 |
| Return on Total Capital | -36.248 |
| Return on Invested Capital | -40.004 |
XBIO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |